Sutro Biopharma, Inc. (STRO)
8.60
-0.12
(-1.38%)
USD |
NASDAQ |
Nov 20, 16:00
8.60
0.00 (0.00%)
After-Hours: 20:00
Sutro Biopharma Enterprise Value : 259.58M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 259.58M |
| November 19, 2026 | 261.57M |
| November 18, 2026 | 257.92M |
| November 17, 2026 | 264.89M |
| November 16, 2026 | 271.53M |
| November 13, 2026 | 279.83M |
| November 12, 2026 | 276.01M |
| November 11, 2026 | 287.13M |
| November 10, 2026 | 285.64M |
| November 09, 2026 | 292.94M |
| November 06, 2026 | 276.51M |
| November 05, 2026 | 269.54M |
| November 04, 2026 | 281.82M |
| November 03, 2026 | 274.68M |
| November 02, 2026 | 268.05M |
| October 30, 2026 | 267.88M |
| October 29, 2026 | 268.54M |
| October 28, 2026 | 271.03M |
| October 27, 2026 | 264.06M |
| October 26, 2026 | 264.31M |
| October 23, 2026 | 271.70M |
| October 22, 2026 | 287.63M |
| October 21, 2026 | 295.93M |
| October 20, 2026 | 308.38M |
| October 19, 2026 | 303.65M |
| Date | Value |
|---|---|
| October 16, 2026 | 298.42M |
| October 15, 2026 | 307.05M |
| October 14, 2026 | 291.45M |
| October 13, 2026 | 299.58M |
| October 12, 2026 | 337.26M |
| October 09, 2026 | 353.69M |
| October 08, 2026 | 371.12M |
| October 07, 2026 | 360.17M |
| October 06, 2026 | 356.68M |
| October 05, 2026 | 367.97M |
| October 02, 2026 | 371.62M |
| October 01, 2026 | 381.91M |
| September 30, 2026 | 384.24M |
| September 29, 2026 | 352.38M |
| September 28, 2026 | 351.22M |
| September 25, 2026 | 350.39M |
| September 24, 2026 | 345.91M |
| September 23, 2026 | 346.24M |
| September 22, 2026 | 352.88M |
| September 21, 2026 | 356.52M |
| September 18, 2026 | 339.78M |
| September 17, 2026 | 342.10M |
| September 16, 2026 | 344.09M |
| September 15, 2026 | 360.00M |
| September 14, 2026 | 365.80M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.052B |
| Alnylam Pharmaceuticals, Inc. | 18.66B |
| Anika Therapeutics, Inc. | 158.39M |
| Savara, Inc. | 776.30M |
| Arrowhead Pharmaceuticals, Inc. | 6.053B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.49M |
| Revenue (Quarterly) | 9.098M |
| Total Expenses (Quarterly) | 40.59M |
| EPS Diluted (Quarterly) | -1.899 |
| Gross Profit Margin (Quarterly) | 86.33% |
| Profit Margin (Quarterly) | -346.1% |
| Earnings Yield | -146.7% |
| Normalized Earnings Yield | -142.37 |